Reda Ahmed, Kamel Mostafa, Loay Mohamed, Abdelsalam Yaser M, Zarzour Mohamed A
Department of Urology, Assiut University Hospital, Assiut, Egypt.
Curr Urol. 2024 Dec;18(4):278-282. doi: 10.1097/CU9.0000000000000206. Epub 2024 Dec 20.
The lifetime occurrence of urinary stones is approximately 1%-15%, and the peak age of occurrence is 30 years. Approximately one fifths of urinary tract stones are found in the ureter, of which two thirds are in the distal ureter. Many drugs, including phosphodiesterase-5 inhibitors (PDE5Is) and α-blockers, are used to relax the smooth muscles in medical expulsive therapy (MET). We aimed to compare the combination of tadalafil and tamsulosin versus tadalafil alone as MET for stones in the L1/3 ureter of 10 mm or less.
A total of 150 patients with L1/3 ureteric stones measuring 10 mm or less were enrolled in the study and randomly assigned to one of 3 equal groups using a computer-generated random number. Patients in group A prescribed tadalafil 10 mg/d. However, those in group B were prescribed tamsulosin 0.4 mg and tadalafil 10 mg/d, whereas those in group C received a placebo once daily. Stone expulsion rate and pain recurrence were evaluated after 14 days.
The stone expulsion rate was significantly higher in the tadalafil and tamsulosin groups and the tamsulosin group than in the placebo group in the current study by 68% in the combination group, 64% in the tadalafil alone group, and 42% in the placebo group ( = 0.019). In the current study, a combination was associated with lower pain recurrence than tadalafil alone or placebo, with means of 1.06, 1.9, 2.98 (with a p value of 0.001). Stone size was not effective in any group.
The combination of PDE5Is and α-blockers effectively increases the expulsion of lower ureteric stones (5-10 mm), but with the same effect as PDE5Is alone, with the advantage of decreasing pain recurrence. Stone size did not affect the expulsion rate in patients who received MET for stones less than 1 cm in size.
尿路结石的终生发病率约为1%-15%,发病高峰年龄为30岁。约五分之一的尿路结石位于输尿管,其中三分之二位于输尿管下段。许多药物,包括磷酸二酯酶-5抑制剂(PDE5Is)和α受体阻滞剂,被用于药物排石治疗(MET)中使平滑肌松弛。我们旨在比较他达拉非与坦索罗辛联合用药与单独使用他达拉非作为MET治疗长度在10毫米及以下的L1/3段输尿管结石的效果。
本研究共纳入150例L1/3段输尿管结石长度在10毫米及以下的患者,并使用计算机生成的随机数将其随机分为3个相等的组。A组患者每天服用10毫克他达拉非。然而,B组患者每天服用0.4毫克坦索罗辛和10毫克他达拉非,而C组患者每天服用一次安慰剂。14天后评估结石排出率和疼痛复发情况。
在本研究中,他达拉非与坦索罗辛联合用药组和坦索罗辛组的结石排出率显著高于安慰剂组,联合用药组为68%,单独使用他达拉非组为64%,安慰剂组为42%(P = 0.019)。在本研究中,联合用药组的疼痛复发率低于单独使用他达拉非组或安慰剂组,平均值分别为1.06、1.9、2.98(P值为0.001)。结石大小在任何一组中均无影响。
PDE5Is与α受体阻滞剂联合用药可有效提高下段输尿管结石(5-10毫米)的排出率,但与单独使用PDE5Is效果相同,且具有降低疼痛复发的优势。结石大小对接受MET治疗的结石小于1厘米的患者的排出率没有影响。